CymaBay Therapeutics (NASDAQ:CBAY) shares traded down 8.5% during trading on Monday . The company traded as low as $12.28 and last traded at $12.30. 867,585 shares traded hands during trading, a decline of 26% from the average session volume of 1,168,808 shares. The stock had previously closed at $13.44.
A number of research analysts have recently commented on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a report on Friday, March 16th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target (up from $12.00) on shares of CymaBay Therapeutics in a report on Wednesday, January 24th. Piper Jaffray reiterated a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a report on Friday, March 16th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 10th. Finally, Leerink Swann upped their price target on CymaBay Therapeutics from $16.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, April 11th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $18.78.
The stock has a market cap of $722.25, a PE ratio of -15.18 and a beta of 2.06. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.04.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.06. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $1.25 million. equities analysts forecast that CymaBay Therapeutics will post -0.9 EPS for the current fiscal year.
In other news, Director Carl Goldfischer sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $13.03, for a total transaction of $195,450.00. Following the sale, the director now directly owns 9,340 shares in the company, valued at $121,700.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kurt Von Emster sold 218,057 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $15.89, for a total value of $3,464,925.73. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 533,179 shares of company stock worth $7,367,706. 15.10% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. bought a new stake in CymaBay Therapeutics in the fourth quarter valued at $115,000. Goldman Sachs Group Inc. bought a new stake in CymaBay Therapeutics in the fourth quarter valued at $197,000. Virtu Financial LLC grew its position in CymaBay Therapeutics by 56.2% in the fourth quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 8,899 shares during the period. Sigma Planning Corp grew its position in CymaBay Therapeutics by 82.0% in the fourth quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 12,300 shares during the period. Finally, Wells Fargo & Company MN grew its position in CymaBay Therapeutics by 7,729.2% in the fourth quarter. Wells Fargo & Company MN now owns 39,146 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 38,646 shares during the period. Hedge funds and other institutional investors own 58.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: “CymaBay Therapeutics (CBAY) Shares Down 8.5%” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/25/cymabay-therapeutics-cbay-shares-down-8-5.html.
About CymaBay Therapeutics
Cymabay Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.